Investors bought shares of Eli Lilly and Co. (NYSE:LLY) on weakness during trading hours on Thursday. $63.20 million flowed into the stock on the tick-up and $43.04 million flowed out of the stock on the tick-down, for a money net flow of $20.16 million into the stock. Of all stocks tracked, Eli Lilly and had the 22nd highest net in-flow for the day. Eli Lilly and traded down ($0.70) for the day and closed at $79.32

Several equities analysts recently weighed in on the stock. Leerink Swann reaffirmed a “buy” rating on shares of Eli Lilly and in a research report on Sunday, June 26th. Morgan Stanley reaffirmed a “hold” rating and set a $88.00 price objective on shares of Eli Lilly and in a research report on Saturday, June 4th. Vetr lowered shares of Eli Lilly and from a “strong-buy” rating to a “buy” rating and set a $85.08 price objective on the stock. in a research report on Monday, April 18th. Deutsche Bank AG reaffirmed a “buy” rating on shares of Eli Lilly and in a research report on Sunday, March 27th. Finally, Jefferies Group reaffirmed a “buy” rating and set a $100.00 price objective on shares of Eli Lilly and in a research report on Friday, May 13th. Four research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $94.86.

The firm has a market capitalization of $84.43 billion and a price-to-earnings ratio of 36.71. The stock’s 50-day moving average price is $75.41 and its 200-day moving average price is $76.14.

Eli Lilly and (NYSE:LLY) last posted its quarterly earnings data on Tuesday, April 26th. The company reported $0.83 earnings per share for the quarter, missing the consensus estimate of $0.85 by $0.02. The business earned $4.87 billion during the quarter, compared to analysts’ expectations of $4.82 billion. Eli Lilly and’s revenue for the quarter was up 4.7% on a year-over-year basis. During the same quarter last year, the firm earned $0.87 EPS. Equities analysts predict that Eli Lilly and Co. will post $3.57 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 9th. Shareholders of record on Monday, August 15th will be given a dividend of $0.51 per share. This represents a $2.04 annualized dividend and a yield of 2.56%. The ex-dividend date of this dividend is Thursday, August 11th.

In other news, CAO Donald A. Zakrowski sold 1,600 shares of the stock in a transaction on Monday, May 2nd. The stock was sold at an average price of $75.86, for a total transaction of $121,376.00. Following the sale, the chief accounting officer now directly owns 3,113 shares of the company’s stock, valued at approximately $236,152.18. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP Alfonso G. Zulueta sold 12,000 shares of the stock in a transaction on Wednesday, April 27th. The stock was sold at an average price of $76.27, for a total value of $915,240.00. Following the sale, the senior vice president now directly owns 45,101 shares in the company, valued at $3,439,853.27. The disclosure for this sale can be found here.

Several hedge funds recently added to or reduced their stakes in LLY. Dimensional Fund Advisors LP raised its stake in Eli Lilly and by 7.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,488,271 shares of the company’s stock valued at $125,422,000 after buying an additional 105,381 shares during the period. BNP Paribas Arbitrage SA raised its stake in Eli Lilly and by 81.8% in the fourth quarter. BNP Paribas Arbitrage SA now owns 272,917 shares of the company’s stock valued at $22,996,000 after buying an additional 122,779 shares during the period. Dorsey & Whitney Trust CO LLC raised its stake in Eli Lilly and by 1.2% in the fourth quarter. Dorsey & Whitney Trust CO LLC now owns 20,579 shares of the company’s stock valued at $1,734,000 after buying an additional 239 shares during the period. Stephens Inc. AR raised its stake in Eli Lilly and by 10.7% in the fourth quarter. Stephens Inc. AR now owns 35,447 shares of the company’s stock valued at $2,987,000 after buying an additional 3,426 shares during the period. Finally, I.G. Investment Management LTD. raised its stake in Eli Lilly and by 21.4% in the fourth quarter. I.G. Investment Management LTD. now owns 299,426 shares of the company’s stock valued at $25,230,000 after buying an additional 52,713 shares during the period.

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.